Cape Investment Advisory Inc. Acquires 818 Shares of GSK plc (NYSE:GSK)

Cape Investment Advisory Inc. boosted its holdings in GSK plc (NYSE:GSK) by 12.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 7,184 shares of the pharmaceutical company’s stock after acquiring an additional 818 shares during the quarter. Cape Investment Advisory Inc.’s holdings in GSK were worth $243,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC increased its position in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after acquiring an additional 259,867 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after acquiring an additional 342,365 shares in the last quarter. Equity Investment Corp raised its position in shares of GSK by 13.3% in the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after purchasing an additional 466,327 shares during the last quarter. Finally, Provident Trust Co. boosted its stake in GSK by 1.7% in the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after purchasing an additional 66,765 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

Shares of NYSE GSK opened at $37.59 on Friday. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92. The firm has a market capitalization of $77.90 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The firm has a 50 day moving average of $34.99 and a 200 day moving average of $37.26.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, research analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.